Literature DB >> 29740196

Quality improvement initiative to improve inpatient outcomes for Neonatal Abstinence Syndrome.

Elisha M Wachman1, Matthew Grossman2, Davida M Schiff3,4, Barbara L Philipp3, Susan Minear3, Elizabeth Hutton3, Kelley Saia5, Fnu Nikita6, Ahmad Khattab7, Angela Nolin7, Crystal Alvarez6, Karan Barry3, Ginny Combs3, Donna Stickney3, Jennifer Driscoll3, Robin Humphreys3, Judith Burke3, Camilla Farrell8, Hira Shrestha3, Bonny L Whalen9.   

Abstract

OBJECTIVES: To improve Neonatal Abstinence Syndrome (NAS) inpatient outcomes through a comprehensive quality improvement (QI) program.
DESIGN: Inclusion criteria were opioid-exposed infants ≥36 weeks. QI methodology including stakeholder interviews and plan-do-study-act (PDSA) cycles were utilized. We compared pre- and post-intervention NAS outcomes after a QI initiative that included: A non-pharmacologic care bundle, function-based assessments consisting of symptom prioritization and then the "Eat, Sleep, Console" (ESC) Tool; and a switch to methadone for pharmacologic treatment.
RESULTS: Pharmacologic treatment decreased from 87.1 to 40.0%; adjunctive agent use from 33.6 to 2.4%; hospitalization length from a mean 17.4 to 11.3 days, and opioid treatment days from 16.2 to 12.7 (p < 0.001 for all). Total hospital charges decreased from $31,825 to $20,668 per infant. Parental presence increased from 55.6 to 75.8% (p < 0.0001). No adverse events were noted.
CONCLUSIONS: A comprehensive QI program focused on non-pharmacologic care, function-based assessments, and methadone resulted in significant sustained improvements in NAS outcomes. These findings have important implications for establishing potentially better practices for opioid-exposed newborns.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29740196     DOI: 10.1038/s41372-018-0109-8

Source DB:  PubMed          Journal:  J Perinatol        ISSN: 0743-8346            Impact factor:   2.521


  24 in total

Review 1.  Optimal Care for NAS: Are We Moving in the Wrong Direction?

Authors:  Lauren M Jansson; Martha L Velez
Journal:  Hosp Pediatr       Date:  2019-08

Review 2.  Beyond the Finnegan scoring system: Novel assessment and diagnostic techniques for the opioid-exposed infant.

Authors:  Davida M Schiff; Matthew R Grossman
Journal:  Semin Fetal Neonatal Med       Date:  2019-01-28       Impact factor: 3.926

3.  Association between prenatal opioid exposure, neonatal opioid withdrawal syndrome, and neurodevelopmental and behavioral outcomes at 5-8 months of age.

Authors:  Ludmila N Bakhireva; Bradley D Holbrook; Shikhar Shrestha; Yuridia Leyva; Malia Ashley; Sandra Cano; Jean Lowe; Julia M Stephen; Lawrence Leeman
Journal:  Early Hum Dev       Date:  2018-12-13       Impact factor: 2.079

4.  Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects.

Authors:  Elisha M Wachman; Kelley Saia; Melissa Miller; Eduardo Valle; Hira Shrestha; Ginny Carter; Martha Werler; Hendree Jones
Journal:  Clin Ther       Date:  2019-07-27       Impact factor: 3.393

5.  The ACT NOW Clinical Practice Survey: Gaps in the Care of Infants With Neonatal Opioid Withdrawal Syndrome.

Authors:  Jessica N Snowden; A Akshatha; Robert D Annett; Margaret M Crawford; Abhik Das; Lori A Devlin; Rosemary D Higgins; Zhuopei Hu; Elizabeth Lindsay; Stephanie Merhar; Clare Campbell Nesmith; Heather Pratt-Chavez; Judith Ross; Alan E Simon; M Cody Smith; Christine B Turley; Anita Walden; Leslie Young; Bonny Whalen
Journal:  Hosp Pediatr       Date:  2019-07-19

6.  Hospital Outcomes of Infants with Neonatal Opioid Withdrawal Syndrome at a Tertiary Care Hospital with High Rates of Concurrent Nonopioid (Polysubstance) Exposure.

Authors:  Erin Morris; Tyler Bardsley; Krista Schulte; Jeanette Seidel; Julie H Shakib; Karen F Buchi; Camille M Fung
Journal:  Am J Perinatol       Date:  2020-09-06       Impact factor: 1.862

Review 7.  Reconceptualizing non-pharmacologic approaches to Neonatal Abstinence Syndrome (NAS) and Neonatal Opioid Withdrawal Syndrome (NOWS): A theoretical and evidence-based approach.

Authors:  Martha L Velez; Chloe J Jordan; Lauren M Jansson
Journal:  Neurotoxicol Teratol       Date:  2021-08-19       Impact factor: 3.763

8.  Length of Stay Among Infants with Neonatal Abstinence Syndrome and Risk of Hospital Readmission.

Authors:  Hafsatou Diop; Xiaohui Cui; Timothy Nielsen; Elizabeth Peacock-Chambers; Munish Gupta
Journal:  Matern Child Health J       Date:  2022-07-30

9.  The Colorado Hospitals Substance Exposed Newborn Quality Improvement Collaborative: Standardization of Care for Opioid-Exposed Newborns Shortens Length of Stay and Reduces Number of Infants Requiring Opiate Therapy.

Authors:  Sunah S Hwang; Blair Weikel; Jillian Adams; Stephanie L Bourque; Jaime Cabrera; Nancy Griffith; Anne M Hall; Jessica Scott; Danielle Smith; Colleen Wheeler; Jade Woodard; Erica Wymore
Journal:  Hosp Pediatr       Date:  2020-08-07

Review 10.  Economic Evaluation of Interventions for Treatment of Neonatal Opioid Withdrawal Syndrome: A Review.

Authors:  Evelyn Lee; Deborah Schofield; Syeda Ishra Azim; Ju Lee Oei
Journal:  Children (Basel)       Date:  2021-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.